Impact of SARS-Cov-2 infection in patients with hypertrophic cardiomyopathy: results of an international multicentre registry.
Juan Ramon Gimeno-BlanesIacopo OlivottoAna Isabel RodríguezCarolyn Y HoAdrián FernándezAlejandro QuirogaMari Angeles EspinosaCristina Gómez-GonzálezMaría RobledoLucas Tojal-SierraSharlene M DayAnjali OwensRoberto Barriales VillaJose María LarrañagaJosé F Rodriguez PalomaresMaribel González-Del-HoyoJesús Piqueras-FloresNosheen RezaOlga ChumakovaEuan A AshleyVictoria ParikhMatthew WheelerDaniel JacobyAlexandre C PereiraSara SaberiAdam S HelmsEduardo VillacortaMaría Gallego DelgadoDaniel de CastroFernando DomínguezTomas Ripoll-VeraEsther Zorio-GrimaJosé Carlos Sánchez-MartínezAna García-ÁlvarezElena ArbeloMaría Victoria MogollónMaría Eugenia Fuentes-CañameroElias GrandeCarlos PeñaLorenzo MonserratNeal K Lakdawalanull nullPublished in: ESC heart failure (2022)
Over one-fourth of HCM patients infected with SARS-Cov-2 required hospitalization, including 6% in an ICU setting. Age and cardiac features related to HCM, including baseline functional class, left ventricular outflow tract obstruction, and systolic impairment, conveyed increased risk of mortality.
Keyphrases
- hypertrophic cardiomyopathy
- left ventricular
- sars cov
- heart failure
- cardiac resynchronization therapy
- acute myocardial infarction
- left atrial
- mitral valve
- aortic stenosis
- ejection fraction
- respiratory syndrome coronavirus
- newly diagnosed
- intensive care unit
- prognostic factors
- clinical trial
- cardiovascular events
- blood pressure
- randomized controlled trial
- coronary artery disease
- mechanical ventilation
- cardiovascular disease
- patient reported
- type diabetes
- drug induced
- percutaneous coronary intervention